Nachrichten zur Hims & Hers Health Aktie

Hims & Hers Stock (HIMS) Soars after RFK Jr. Signals Looser Rules on Peptide Treatments

Hims Hers Health ($HIMS) surged more than 14% on Wednesday after the U.S. Health Secretary Robert F. Kennedy Jr.…

Hims & Hers Stock Surges 30%: GLP-1 Momentum Fuels Rebound Despite Regulatory and Revenue Headwinds

Hims & Hers Health rallies sharply on renewed optimism around its GLP-1 weight-loss strategy, signaling a potential shift in momentum...…

Hims and Hers Stock Surges 30%: GLP-1 Momentum Fuels Rebound Despite Regulatory and Revenue Headwinds

After months of decline, Hims & Hers Health recovers dramatically on newfound optimism about their GLP-1 weight-loss method, suggesting a…

Hims Jumps as RFK Jr. Seeks to Loosen Peptide Regulations

Hims & Hers Health Inc. surged as much as 12% after Health Secretary Robert F. Kennedy Jr. said US drug…

Hims & Hers: A Forced Pivot Tests the Telehealth Model

Telehealth firm Hims & Hers shifts strategy after FDA action, now selling branded Wegovy. Despite st…

Hims & Hers Health stock gains as ZAVA and Livewell acquisitions boost international sales

Hims & Hers Health rises 2.06% today to $21.80, showing short-term strength but faces resistance above. Latest insights inside.…

Why is Hims & Hers Health stock up today?

Hims & hers health gains 2.81% today, trading at $21.96 amid mixed technical signals and higher intraday volatility.…

Applauding FDAs Move Towards Regulatory Clarity on Peptide Therapy

Hims & Hers Chief Medical Officer, Dr. Pat Carroll, on FDAs move towards updated guidance regarding several peptides.…

Hims & Hers: Bargain EBITDA Multiples As GLP-1 Drama Passes

Hims & Hers stock is down ~40% YTD but remains a "Buy." Learn why compressed valuation and Eucalyptus-led Europe/Japan expansion…

Evaluating Hims & Hers Health (HIMS) Valuation After Weight Loss Crackdown And Wegovy Pivot

Hims & Hers Health (HIMS) is under close watch after US regulators forced an immediate stop to its compounded weight…

Modest gains for Hims & Hers Health stock as $21.38 resistance remains in focus

Hims & Hers Health trades at $21.24 today, up 0.43%. See the latest price action, news, and technical outlook for…

Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine…

Hims & Hers Health Inc (HIMS) Shares Surge 8.8% -- What GF Score of 76 Tells Investors

On April 13, 2026, Hims & Hers Health Inc (HIMS) shares rose 8.8% to a current price of $21.15. The…

Hims & Hers to Announce First Quarter 2026 Financial Results on May 11, 2026

SAN FRANCISCO--(BUSINESS WIRE)--Apr 13, 2026--…

Hims & Hers schedules May 11 earnings release, 5 p.m. ET call

A live webcast starts at 5 p.m. ET and will stay archived for one year. Investors also get a June…

Hims & Hers Health (HIMS) jumps 9.8% as GLP-1 partnership momentum returns to focus

Hims & Hers Health (HIMS) is up 9.8% today. Here is some analysis on what might have caused this price…

Hims & Hers Health Stock Surges on Breakthrough Shift

Hims & Hers Health ( ($HIMS) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual…

Hims & Hers Health stock rises as sellers remain in control of the short-term trend

Hims & Hers Health climbs 4.55% to $20.32 today. Latest price action, technicals, and forecast for HIMS/USD.…

Hims & Hers to Announce First Quarter 2026 Financial Results on May 11, 2026

Hims Hers Health, Inc. (“Hims Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it…

Hims & Hers (HIMS) Shifts Beyond GLP-1 Controversy to Long-Term Health Platform

Hims Hers ($HIMS) is moving from the controversy surrounding glucagon-like peptide-1 (GLP-1) to a long-term health platform. Not that…

Okta breach chain hits Hims & Hers in wider ShinyHunters attack spree

Hackers used Okta access to breach Hims & Hers support systems, exposing customer data in a wider ShinyHunters-linked attack pattern…

Hims & Hers Grapples with Legal and Security Woes During Critical Pivot

Hims & Hers navigates a shareholder lawsuit, a data breach, and a major pivot to lower-margin GLP-1…

A Look At Hims & Hers (HIMS) Valuation After GLP 1 Crackdown And Wegovy Pivot

The regulatory halt of Hims & Hers Health (HIMS) compounded weight loss drugs, along with its shift to distributing branded…

Hims And Hers Confronts Amazon Threat While Advancing AI Weight Loss Plan

Amazon Pharmacy has entered the weight loss medication market with Eli Lilly’s new GLP-1 drug, offering same day delivery and…

Hims & Hers CEO gifts 845,866 company shares

Hims & Hers CEO Andrew Dudum reports a bona fide gift of 845,866 Class A shares, with 887,684 shares still…

Is It Time To Reassess Hims & Hers Health (HIMS) After The Recent Share Price Pullback?

If you are wondering whether Hims & Hers Health at around US$19.75 is starting to look attractive or still pricing…

Hims & Hers: A Telehealth Giants Rocky Transition

Hims & Hers stock trades 70% below its high after a data breach, a forced pivot to costly branded we…

Hims & Hers Health stock price forecast: $21.38 resistance in focus as HIMS drops 1.87%

Hims & Hers Health trades at $19.38 today, down 1.87%. Bearish signals dominate, with volatility expected in the coming days.…

Why Is HIMS Stock Down 40%?

Hims & Hers (HIMS) stock is down roughly 40% YTD, a massive underperformance driven entirely by a sudden regulatory crackdown…

Why Is HIMS Stock Down 40%?

Hims & Hers (HIMS) stock is down roughly 40% YTD, a massive underperformance driven entirely by a sudden regulatory crackdown…

Hims & Hers Stock Plunges Amid Strategic Pivot and Security Breach

Hims & Hers stock nears 52-week low due to weight-loss strategy pivot, cybersecurity breach, and CFO…

Hims & Hers (HIMS) Stock Plummets 39% Amid GLP-1 Strategy Shift and Margin Pressure

Hims & Hers (HIMS) stock fell 39% in 2026 after shifting to branded GLP-1 drugs. Amazons Foundayo launch adds pressure.…

Hims & Hers (HIMS) Stock Down 39% as GLP-1 Brand Transition Squeezes Margins

Hims & Hers (HIMS) stock is down 39% in 2026 as its GLP-1 brand pivot pressures margins and Amazon enters…

Hims & Hers’ Shift to Branded Obesity Drugs Pressures Stock — Will the Bet Pay Off?

After a dramatic legal battle with Novo Nordisk ($NVO), U.S. low-cost healthcare services provider Hims Hers ($HIMS) late last…

Hims & Hers price target slashed amid GLP-1 transition

Bank of America lowered its 2026 price target for Hims & Hers (NYSE:HIMS) to $21 from $23, citing peer multiple…

Hims & Hers price target slashed amid GLP-1 transition

Bank of America lowered its 2026 price target for Hims & Hers (NYSE:HIMS) to $21 from $23, citing peer multiple…

Hims & Hers Health stock rises as FDA-approved Wegovy and Ozempic come back to market

Hims & Hers Health trades at $19.82, up 1.66% today, but remains under pressure with weak momentum and technical resistance…

Hims & Hers Health Is No Longer What The Market Thinks

Hims & Hers is evolving from a telehealth provider into a scalable, global consumer health platform with diversified growth drivers.…

Hims & Hers Health (HIMS) Is Down 6.1% After Expanding GLP-1 Access With Novo Nordisk Collaboration

U.S. stocks, Saudi stocks, stock trading and investment platforms…

Hims & Hers Health (HIMS) Is Down 6.1% After Expanding GLP-1 Access With Novo Nordisk Collaboration

In late March 2026, Hims & Hers Health announced a renewed collaboration with Novo Nordisk, adding a broad range of…

Hims & Hers price target slashed amid GLP-1 transition

Bank of America lowered its 2026 price target for Hims & Hers (NYSE:HIMS) to $21 from $23, citing peer multiple…

Hims & Hers price target slashed amid GLP-1 transition

Bank of America lowered its 2026 price target for Hims & Hers (NYSE:HIMS) to $21 from $23, citing peer multiple…

Hims & Hers expects to issue over 100,000 Wegovy prescriptions per month

The online pharmacy is switching from generic drugs to brand-name medications and aims to capture a significant share of the…

Hims & Hers price target lowered to $21 from $23 at BofA

BofA analyst Allen Lutz lowered the firm’s price target on Hims Hers to $21 from $23 and keeps a…

BofA cuts Hims and Hers stock price target on EBITDA concerns

BofA cuts Hims and Hers stock price target on EBITDA concerns…

Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts

In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $19.5, denoting a -4.08%…

Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts

In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $19.5, denoting a -4.08%…

Hims & Hers Health (HIMS) Is Up 8.3% After Expanding Novo Nordisk GLP-1 Partnership And Launching New Weight-Loss Membership - Has The Bull Case Changed?

In late March 2026, Hims & Hers Health, Inc. announced a renewed collaboration with Novo Nordisk to offer a broad…

Hims & Hers Health stock falls as insider files to sell shares

Hims & Hers Health stock falls as insider files to sell shares…

Hims & Hers Health stock falls as insider files to sell shares

Hims & Hers Health stock falls as insider files to sell shares…